Autolus Therapeutics PLC
NASDAQ:AUTL
Intrinsic Value
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. [ Read More ]
The intrinsic value of one
AUTL
stock under the Base Case scenario is
11.69
USD.
Compared to the current market price of 4.01 USD,
Autolus Therapeutics PLC
is
Undervalued by 66%.
Autolus Therapeutics PLC's market capitalization is 1.1B USD.
AUTL stock price is 4.01 USD.
AUTL stock price (4.01 USD) is 66% less than its Intrinsic Value (11.69 USD).
AUTL. Open DCF Valuation
AUTL stock price (4.01 USD) is 66% less than its Relative Value (11.69 USD). Open Relative Valuation
AUTL has upside potential of 172% compared to the average analyst price target.
Open Wall St Estimates
AUTL's Revenue has been falling by 0% per year for the last 3 years.
AUTL's ROIC (Return on Invested Capital) has decreased in the last 3 years from -142% to -144%, and is approaching profitability.
AUTL's long-term assets (375m USD) exceed its long-term liabilties (264m USD).
AUTL's Revenue has dropped by 73% over the past 12 months.
AUTL's ROE (Return on Equity) has significantly decreased in the last 3 years from -50% to -102%, and is approaching profitability.
AUTL has negative Operating Income for the last twelve months.
AUTL has negative Net Income for the last twelve months.
AUTL's ROE (Return on Equity) for the past 12 months is negative and is equal to -102%.
AUTL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -144%.
AUTL's Revenue is forecast to grow at a rate of 409% per year over the next 3 years.
AUTL has negative Free Cash Flow for the last twelve months.
AUTL has negative three-year average ROE (Return on Equity): -65%. The company is not efficient at transforming stockholders' equity into net income.
AUTL has negative three-year average ROIC (Return on Invested Capital): -133%. The company is not efficient at using invested capital to generate operating income.
AUTL's short-term assets (275m USD) exceed its short-term liabilties (45m USD).
AUTL's D/E (Debt to Equity) is very low and is equal to 0.
AUTL's Altman Z-Score is very low and is equal to -0.95.
Valuation Backtest
Autolus Therapeutics PLC
Run backtest to discover the historical profit from buying and selling
AUTL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Autolus Therapeutics PLC
Balance Sheet Decomposition
Autolus Therapeutics PLC
| Current Assets | 275.3m |
| Cash & Short-Term Investments | 239.6m |
| Receivables | 24.5m |
| Other Current Assets | 11.2m |
| Non-Current Assets | 100.1m |
| PP&E | 95.7m |
| Other Non-Current Assets | 4.4m |
| Current Liabilities | 44.7m |
| Accounts Payable | 103k |
| Accrued Liabilities | 44.1m |
| Other Current Liabilities | 533k |
| Non-Current Liabilities | 219.2m |
| Other Non-Current Liabilities | 219.2m |
Earnings Waterfall
Autolus Therapeutics PLC
|
Revenue
|
1.7m
USD
|
|
Operating Expenses
|
-177.2m
USD
|
|
Operating Income
|
-175.5m
USD
|
|
Other Expenses
|
-32.9m
USD
|
|
Net Income
|
-208.4m
USD
|
Free Cash Flow Analysis
Autolus Therapeutics PLC
AUTL Profitability Score
Profitability Due Diligence
Autolus Therapeutics PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Autolus Therapeutics PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
AUTL Solvency Score
Solvency Due Diligence
Autolus Therapeutics PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Autolus Therapeutics PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AUTL Price Targets Summary
Autolus Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
AUTL
is 10.9 USD
with a low forecast of 6.97 USD and a high forecast of 16.8 USD.
Shareholder Return
AUTL Price
Autolus Therapeutics PLC
| Average Annual Return | -44.87% |
| Standard Deviation of Annual Returns | 15.69% |
| Max Drawdown | -93% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 265 926 000 |
| Percentage of Shares Shorted | 2.07% |
AUTL News
Last Important Events
Autolus Therapeutics PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Autolus Therapeutics PLC
Company Profile
Autolus Therapeutics PLC
Country
Industry
Market Cap
Dividend Yield
Description
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
Contact
IPO
Employees
Officers
The intrinsic value of one
AUTL
stock under the Base Case scenario is
11.69
USD.
Compared to the current market price of 4.01 USD,
Autolus Therapeutics PLC
is
Undervalued by 66%.
You don't have any saved screeners yet
